Niacin (250mg)

DRUG2 trials

Sponsors

Yale University, Université de Sherbrooke

Conditions

Liver Fibrosis/NASHMetabolic Dysfunction-associated Steatotic Liver Disease (MASLD)Non-Alcoholic Steato-Hepatitis (NASH)Obsessive-Compulsive Disorder

Phase 1

Efficacy of Psilocybin in OCD: a Double-Blind, Placebo-Controlled Study.

CompletedNCT03356483

Yale UniversityObsessive-Compulsive Disorder

Start: 2018-11-13End: 2024-07-25Updated: 2024-11-20

Unknown Phase

Stimulating Fat Tissue Storage With Niacin to Reduce Fat Accumulation in the Liver.

RecruitingNCT06843148

Université de SherbrookeLiver Fibrosis/NASH, Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-Alcoholic Steato-Hepatitis (NASH)

Start: 2026-06-22End: 2030-07-01Target: 36Updated: 2026-07-02

Related Papers

Psilocybin for Treatment-Resistant OCD: A Randomized Controlled Trial

2026-01-15

Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings

Frontiers in Psychiatry2024-01-098 citations

Safety, tolerability, and clinical and neural effects of single-dose psilocybin in obsessive–compulsive disorder: protocol for a randomized, double-blind, placebo-controlled, non-crossover trial

Frontiers in Psychiatry2023-04-2525 citations

Single-dose psilocybin for treatment-resistant obsessive-compulsive disorder: A case report

Heliyon2022-12-0126 citations